Outcomes Data Demonstrating Prognostic Value of Cytogen Corporation's PROSTASCINT Published in Peer-Reviewed Journal Urology

PRINCETON, N.J.--(BUSINESS WIRE)--Cytogen Corporation (NASDAQ: CYTO) today reported the publication of data from a large cohort study demonstrating the value of PROSTASCINT® (capromab pendetide) in predicting outcomes for patients with prostate cancer. The study evaluated patients whose PROSTASCINT images showed a localization pattern known as central abdomen uptake (CAU), a finding suggestive of metastatic disease, as compared to those without such findings. In the study, prostate cancer-specific death rates were 10 times higher in patients with CAU than in patients without CAU (p=0.005).